Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders : Report of Nine Cases
Öz
Objective: We aimed to report our nine Neuromyelitis Optica (NMO) and NMO Spectrum Disorders (NMOSD) cases which have different presentations.
Patients and Methods: In this observational
retrospective study, conducted between September 2011 and September
Results: We had 9 patients (8 female, 1 male). The mean age at onset was 49 years (36-67). While 7 patients were diagnosed with NMO, 2 patients’ diagnoses were NMOSD. The Case 6 was admitted to our clinic with an LETM (longitudinally extensive transverse myelitis) attack after 4 months of chemotherapy and radiotherapy treatment for gallbladder adenocancer. The Case 8 experienced LETM after the diagnosis of pulmonary tuberculosis and under anti-tuberculosis treatment, and the Case 9 was presented with LETM after post-vaccination. Optic nerve and spinal cord involvement occurred simultaneously in three patients. In three cases, optic neuritis developed 4 months, 15 months and 5 years after the myelitis attack. The Case 7 was referred to the hospital owing to cranial involvement, following a history of optic neuritis attacks six months earlier. The Case 1 had three recurrent optic neuritis attacks before the last attack of admission which included brain stem involvement and LETM. The Case 4 was receiving low dose interferone beta-1a with diagnosis of MS. NMO-IgG seropositivity was detected in 6 patients.
Conclusion: Most of our patients were female and have relapsing course. Patients who experienced relapses, mostly were seropositive for NMO- IgG.
Anahtar Kelimeler
Neuromyelitis optica,Neuromyelitis optica spectrum disorders
References
- 1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–9.
- 2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805- 15.
- 3. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019–32.
- 4. Sahraian MA, Radue EW, Minagar A. Neuromyelitis Optica Clinical Manifestations and Neuroimaging Features. Neurol Clin 2013; 31: 139–152
- 5. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390–6.
- 6. Cabrera-Gomez JA, Kister I. Conventional brain MRI in neuromyelitis optica. Eur J Neurol 2012; 19: 812–9.
- 7. Dietemann JL, Beigelman C, Rumbach L, Vouge M, Tajahmady T, Faubert C, et al. Multiple sclerosis and corpus callosum atrophy: relationship of MRI findings to clinical data. Neuroradiology 1988; 30: 478–80
- 8. Klawiter EC, Ceccarelli A, Arora A, Jackson J, Bakshi S, Kim G, et al. Corpus Callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis. J Neuroimaging. 2015; 25: 62-7
- 9. Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, et al. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011; 6: e22766.
- 10. Mandler RN. Neuromyelitis optica - Devic’s syndrome, update. Autoimmun Rev 2006; 5: 537–43.